Pharma giant GSK announces major restructuring drive to cut £400m in costs

GlaxoSmithKline has announced a major restructuring programme that will see the company slash £400 million (€449m) in annual costs in an effort to bolster research spending.

The pharma giant said on Wednesday that the savings would be delivered primarily through "supply chain optimisation" and a cut in administrative costs.